Posted inInfectious Diseases news
Doravirine and Islatravir Combination Proves Non-Inferior to B/F/TAF: A New Era for Two-Drug HIV Maintenance
Phase 3 trial results demonstrate that a daily fixed-dose combination of doravirine and islatravir effectively maintains virological suppression in adults with HIV-1, offering a comparable and safe alternative to standard integrase inhibitor-based regimens.